April 17 (Reuters) - Channel Therapeutics Corp CHRO.A:
LIGAND SUBSIDIARY PELTHOS THERAPEUTICS TO COMBINE WITH CHANNEL THERAPEUTICS
CHANNEL THERAPEUTICS CORP - PROPOSED TRANSACTION WILL RAISE $50 MILLION IN EQUITY CAPITAL
CHANNEL THERAPEUTICS CORP - LIGAND IS ENTITLED TO A 13% ROYALTY ON WORLDWIDE SALES OF ZELSUVMI
CHANNEL THERAPEUTICS CORP -COMBINED CO TO OPERATE UNDER NAME PELTHOS THERAPEUTICS INC., TRADE ON NYSE AMERICAN EXCHANGE UNDER TICKER PTHS
CHANNEL THERAPEUTICS CORP - UPON COMPLETION OF DEAL, PLESHA TO BECOME CEO OF COMBINED CO AND KNUETTEL TO BECOME CFO
Source text: ID:nGNX3XSQny
Further company coverage: CHRO.A
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.